Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2012 1
2013 1
2014 1
2015 6
2016 6
2017 12
2018 11
2019 7
2020 9
2021 13
2022 18
2023 8
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang YH, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK; KEYNOTE-564 Investigators. Powles T, et al. Lancet Oncol. 2022 Sep;23(9):1133-1144. doi: 10.1016/S1470-2045(22)00487-9. Lancet Oncol. 2022. PMID: 36055304 Free article. Clinical Trial.
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, Healy CG, Czibere A, Fizazi K. de Bono JS, et al. Among authors: buttigliero c. Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10. Lancet Oncol. 2021. PMID: 34388386 Free article. Clinical Trial.
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA Methylation.
Franceschini GM, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku SY, Sigouros M, Rothmann E, Alonso A, Benelli M, Nardella C, Auh J, Freeman D, Hanratty B, Adil M, Elemento O, Tagawa ST, Feng FY, Caffo O, Buttigliero C, Basso U, Nelson PS, Corey E, Haffner MC, Attard G, Aparicio A, Demichelis F, Beltran H. Franceschini GM, et al. Among authors: buttigliero c. Cancer Discov. 2024 Mar 1;14(3):424-445. doi: 10.1158/2159-8290.CD-23-0754. Cancer Discov. 2024. PMID: 38197680 Free PMC article.
Safety profile of darolutamide versus placebo: a systematic review and meta-analysis.
Turco F, Gillessen S, Treglia G, Fizazi K, Smith MR, Tombal B, Cathomas R, Buttigliero C, Di Maio M, Tucci M, Vogl UM. Turco F, et al. Among authors: buttigliero c. Prostate Cancer Prostatic Dis. 2023 Dec 14. doi: 10.1038/s41391-023-00775-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 38097723 Review.
Darolutamide in Metastatic Prostate Cancer.
Turco F, Tucci M, Buttigliero C. Turco F, et al. Among authors: buttigliero c. N Engl J Med. 2022 Jun 16;386(24):2344. doi: 10.1056/NEJMc2205310. N Engl J Med. 2022. PMID: 35704492 No abstract available.
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy.
Turco F, Tucci M, Delcuratolo MD, Di Stefano RF, Pisano C, Audisio A, Audisio M, Ungaro A, Ortega C, Di Maio M, Scagliotti GV, Buttigliero C. Turco F, et al. Among authors: buttigliero c. Cancer Commun (Lond). 2022 Aug;42(8):683-688. doi: 10.1002/cac2.12340. Epub 2022 Jul 22. Cancer Commun (Lond). 2022. PMID: 35866986 Free PMC article. No abstract available.
86 results